Central nervous system-active drug abused and overdose in children: a worldwide exploratory study using the WHO pharmacovigilance database.
Drug abuse
Drug safety
Overdose
Paediatrics
Pharmacovigilance
Spontaneous reporting system database
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
28
06
2018
accepted:
22
10
2018
revised:
18
10
2018
pubmed:
31
10
2018
medline:
29
1
2019
entrez:
31
10
2018
Statut:
ppublish
Résumé
Recent epidemiological studies have reported an increase in central nervous system (CNS)-active drug abuse rates in paediatric settings, raising several public health concerns. No study to date has explored this issue worldwide. We performed an extensive analysis of drugs abuse/overdose reported for children in the last decade by using the largest pharmacovigilance database, i.e. the VigiBase, collecting adverse drug reaction reports that involved at least one suspect drug belonging to the Anatomical Therapeutic Chemical code "Nervous System" through the Standardised Medical Dictionary for Drug Regulatory Affairs Queries for Drug abuse. 8.682 reports matched our criteria. An increase in reporting activity was observed, starting from 2014; an intentional overdose was reported more frequently than an accidental one, with a difference between age groups. We retrieved 997 reports with death outcome. These referred more to adolescents (n = 538) than subjects of any other paediatric age group. Paracetamol and opioid analgesics were the most common suspect drugs in deaths across all age groups due to hypoxic-ischaemic encephalopathy, brain death, and cardio-respiratory arrest.Conclusion: The number of reports associated with drug abuse and overdose is increasing (for opioid and paracetamol-containing products) and a considerable number of adverse drug reactions are serious. Data on the patterns of use of such medicines from each country may help in implementing strategies of risk-minimisation and renewing healthcare recommendations worldwide. An increased clinical awareness of drug abuse and overdose is warranted, while continuing to provide effective treatments. What is Known: • The large increase in paediatric prescriptions for CNS-active drugs in the last 20 years has recently raised public health concerns about drug abuse and overdose. • No study to date has examined this issue in paediatric patients worldwide. What is New: • The number of paediatric reports associated with CNS drug abuse and intentional overdose is increasing, including those with fatal outcome; over 4 years; more than 35% of the reports was entered from European countries. • Opioid and paracetamol were most frequently suspected for ADRs with fatal outcome across all age groups, due to hypoxic-ischaemic encephalopathy and cardio-respiratory arrest, suggesting the need to implement strategies of risk-minimisation.
Identifiants
pubmed: 30374752
doi: 10.1007/s00431-018-3281-0
pii: 10.1007/s00431-018-3281-0
doi:
Substances chimiques
Central Nervous System Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-172Références
Pediatrics. 1999 Oct;104(4):e39
pubmed: 10506264
Pediatr Emerg Care. 2000 Feb;16(1):26-7
pubmed: 10698139
BMJ. 2001 May 19;322(7296):1203-7
pubmed: 11358770
Am J Psychiatry. 2003 Jun;160(6):1071-7
pubmed: 12777264
Arch Gen Psychiatry. 2003 Dec;60(12):1236-42
pubmed: 14662556
J Am Coll Health. 2005 Jan-Feb;53(4):167-74
pubmed: 15663065
Drug Alcohol Depend. 2006 Jan 4;81(1):37-45
pubmed: 16040201
J Am Coll Health. 2006 Mar-Apr;54(5):269-78
pubmed: 16539219
Pediatrics. 2006 Dec;118(6):2472-80
pubmed: 17142533
Arch Gen Psychiatry. 2007 Sep;64(9):1032-9
pubmed: 17768268
BMJ. 2007 Sep 8;335(7618):462
pubmed: 17823149
J Am Board Fam Med. 2008 Jan-Feb;21(1):45-54
pubmed: 18178702
Am J Psychiatry. 2009 Sep;166(9):992-1001
pubmed: 19528194
Clin Toxicol (Phila). 2011 Dec;49(10):910-41
pubmed: 22165864
N Engl J Med. 2012 Jul 12;367(2):146-55
pubmed: 22784117
Drug Saf. 2012 Dec 1;35(12):1171-82
pubmed: 23072620
J Intern Med. 1990 Jun;227(6):423-8
pubmed: 2351928
Psychiatry Res. 2013 Nov 30;210(1):302-7
pubmed: 23810383
Br J Clin Pharmacol. 2014 Sep;78(3):610-8
pubmed: 24666324
Drug Res (Stuttg). 2015 Apr;65(4):223-4
pubmed: 24668573
Aust N Z J Psychiatry. 2014 Oct;48(10):917-31
pubmed: 24927734
J Community Health. 2015 Feb;40(1):57-61
pubmed: 24927975
Expert Opin Drug Saf. 2014 Sep;13 Suppl 1:S69-78
pubmed: 25171160
Eur Child Adolesc Psychiatry. 2015 Jun;24(6):635-40
pubmed: 25378107
Ann Pharmacother. 2015 Dec;49(12):1298-304
pubmed: 26324354
Int J Environ Res Public Health. 2015 Nov 20;12(11):14842-56
pubmed: 26610536
J Occup Med Toxicol. 2015 Dec 10;10:43
pubmed: 26664414
Int J Psychiatry Clin Pract. 2016;20(1):47-51
pubmed: 26750572
Bull World Health Organ. 2016 May 1;94(5):340-350F
pubmed: 27147764
World J Pediatr. 2017 Feb;13(1):76-83
pubmed: 27457792
Emerg Med Australas. 2016 Dec;28(6):704-710
pubmed: 27696718
Bull World Health Organ. 2017 May 1;95(5):318-319
pubmed: 28479631
Clin Toxicol (Phila). 2018 Jan;56(1):43-50
pubmed: 28691871
J Popul Ther Clin Pharmacol. 2017 Aug 18;24(3):e19-e32
pubmed: 28873291
Paediatr Anaesth. 2017 Nov;27(11):1070-1076
pubmed: 29030938
Front Pharmacol. 2018 Jun 12;9:611
pubmed: 29946258
J Clin Gastroenterol. 1988 Feb;10(1):76-80
pubmed: 3356889